AF and NOACs An UPDATE JULY 2014
description
Transcript of AF and NOACs An UPDATE JULY 2014
AF AND NOACSAN UPDATE JULY 2014
Helen WilliamsConsultant Pharmacist for CV Disease
South London
AF is the leading - and most preventable - cause of embolic stroke
Risk increases with age
Without preventive treatment, approximately 1 in 20 patients (5%) with AF will have a stroke each year
0
5
10
15
20
25
50-59 60-69 70-79 80-89
% of strokes attributable to AF
Kannel WB et al. Am J Cardiol 1998; 82 (8A): 2N–9N.
AF and stroke risk
Age (years)
%
NICE Guidance 2014
NICE Priorities (CG180)
Personalised package of care Assessment of stroke and bleeding risk
Use of CHA2DS2-VASc and HASBLED
Anticoagulation with warfarin or a NOAC Stop using aspirin for stroke
prevention in AF Rate and rhythm control Specialist referral and interventions
where first line options fail to manage symptoms adequately
CHA2DS2-VASc
Score Annual stroke rate, %
0 0
1 1.3
2 2.2
3 3.2
4 4.0
5 6.7
6 9.8
7 9.6
8 6.7
9 15.2
•Congestive heart failure/1
LV dysfunction•Hypertension
1•Age 75
2•Diabetes mellitus
1•Stroke/TIA/TE
2•Vascular disease
1(CAD, CArD, PAD)
•Age 65-741
•Sex category (female)1
Score 0 – 9Validated in 1084 NVAF patients not on OAC with known TE status at 1 year in Euro Heart SurveyOR for stroke if: Female: 2.53 (1.08 – 5.92), p=0.029; Vascular disease: 2.27 (0.94 – 5.46), p=0.063
Assessment of risk of bleeding - HAS-BLED
Pisters R, et al. Chest 2010;138:1093-100
ScoreBleeds per 100 patient-
years
0 1.13
1 1.02
2 1.88
3 3.74
4 8.70
•Hypertension (current)
1
•Abnormal renal/liver function
1/2
•Stroke
1
•Bleeding
1
•Labile INR
1
•Elderly (age > 65 years)
1
•Drugs or alcohol
1/2
Score 0 – 9
Validated in 3978 NVAF patients with known TE status at 1 year in Euro Heart Survey
c-statistic 0.72 (similar to HEMORR2HAGES)0.91 vs 0.85 for patients on ASA or no therapy
Low
Inter-mediate
High
c-statistic 0.72
Myths and Misconceptions…
Aspirin is as effective as oral anticoagulation
Aspirin is safer than oral anticoagulation
Falls are a C/I to anticoagulant therapy
Prior GI bleeds are a C/I to anticoagulation
So, where are we now?
Up to 15% of patients cannot take warfarin due to allergy, contraindication or inability to manage the monitoring requirements.
Up to 40% are not controlled within therapeutic range on warfarin
Up to 45% with atrial fibrillation at high stroke risk are not currently anticoagulated – see QOF!
Where are we now?
50%
55%
60%
65%
70%
75%
80%
85%
90%
95%
100%
Warfarin vs NOACs share (DOT)
WARFARIN NOAC
1. Data on file: Bristol-Myers Squibb Pharmaceuticals Limited
~4% uptake of NOACs in the UK market
DOT = Days on therapy
NOACs: Prioritizing Patients
HIGH PRIORITY
MEDIUM PRIORITY
LOWER PRIORITY
Patients unable to take warfarin due to allergies / CI and patients unable to comply with monitoring of warfarin (n=207)
Patients out of range (n =252 – 501)
New Patients (n=261)
Patients on aspirin or nothing (n= 629-1257)
Patients currently stable on warfarin (n=756 – 1005)£425-
£565k
£147k
£505 - £1,010k
£141 -£282k
£166k
What about costs?** Annual costs based on a CCG in South London, population 300k (prevalence = 0.9%)
= 7 strokes prevented
= 8 -16 strokes prevented
= 20 - 40 strokes prevented
= 3 – 5 strokes
prevented
…. And return on investment?
Plus... up to £915k for currently undetected AF
Novel oral anticoagulantsSW London Positioning 2014/15
An alternative to warfarin for SPAF in patients with CHADS2 ≥ 1 who: have a warfarin allergy, warfarin specific-
contraindication or are unable to tolerate warfarin therapy
are unable to comply with the specific monitoring requirements of warfarin
are unable to achieve a satisfactory INR after an adequate trial of warfarin
have had an ischaemic stroke whilst stable on warfarin therapy
are unwilling to take warfarin after a full discussions of the risks and benefits
SWL Positioning 2014/15
Warfarin is a suitable first-line option for many patients
Initiation by clinicians with ‘expertise in initiating anticoagulation’
Initiating clinician responsible for at least first 3 months of therapy:
Address side effects Emphasise importance of adherence
Transfer to patients own GP when ‘stable’ and in line with approved indications
Prescribing NOACs
Check indication – AF, VTE treatment or prophylaxis Check patient age – dose adjustment at 80 years
with dabigatran Check renal function
Not just eGFR Calculate creatinine
clearance Check for adverse effects
Dabigatran dyspepsia in up to 10% patients Rivaroxaban / apixaban: headache / dizziness
Check adherence No monitoring of bloods (except annual renal function) therefore
possible increased risk of non-adherence over time